Emergent BioSolutions Inc. EBS NYSE · Healthcare · United States
$5.81 -1.36% -$0.08
Summary
36 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 29 USD is left as free cash.
- It bought back its own shares for $24.9M in the last fiscal year, 8.2% of its market value.
What to watch
- The company made a loss over the last 12 months.
- Revenue fell by 13% a year over the last 3 years.
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 14% a year over 5 years. Over the last 3 years it fell by 13% a year.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $260.7M.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.7 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 11
- Hold 3
- Sell 1
Today's price within the analysts' price targets
The average target of $10 is 72% above today's price. 73% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 95%
- Contracts and Grants 5.1%
By region
- UNITED STATES 71%
- Other Geographical Area 18%
- CANADA 10%
Product brings in 95% of revenue.
Segments in detail